Literature DB >> 19801559

Long-term recurrence-free survival in a patient with primary hepatic carcinosarcoma: case report with a literature review.

Yusuke Yamamoto1, Hidenori Ojima, Kazuaki Shimada, Hiroaki Onaya, Nobuyoshi Hiraoka, Yasunori Mizuguchi, Tomoo Kosuge, Yae Kanai.   

Abstract

A 72-year-old man was found to have a 40 mm mass in liver segment VIII during follow-up abdominal ultrasonography for type C viral hepatitis. Abdominal ultrasound showed a well-defined mass containing a cystic component, and computed tomographic hepatic arteriography showed heterogeneous enhancement except for cystic necrosis. Under a pre-operative diagnosis of atypical hepatocellular carcinoma (HCC), partial resection of liver segment VIII was performed. The encapsulated tumor consisted of a peripheral solid component with a central necrotic area. Histologically, the solid component had a two-layer structure, an HCC component in the external area and a sarcomatous component with neoplastic osteoid formation in the internal area, showing histological transition. Immunohistochemically, the HCC component was positive for hepatocyte antigen and negative for vimentin. The Ki-67 labeling index was found to increase from 5% to 58% with increasing histologic atypia. The sarcomatous component was positive for vimentin and negative for pan-keratin and hepatocyte antigen, with a Ki-67 labeling index of >90%. These findings led to a diagnosis of primary hepatic carcinosarcoma. Although previously reported patients with hepatic carcinosarcoma showed early metastasis with a very poor outcome, this patient has remained free of recurrence for 30 months, which is the longest recurrence-free survival time recorded for this type of cancer. Since relatively early-stage hepatic carcinosarcoma rarely seems to present as a small tumor showing a concentric growth pattern, we report this case with a review of the literature.

Entities:  

Mesh:

Year:  2009        PMID: 19801559     DOI: 10.1093/jjco/hyp123

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  Primary combined hepatocellular-cholangiocellular sarcoma: An unusual case.

Authors:  Shuai Xiang; Yi-Fa Chen; Yan Guan; Xiao-Ping Chen
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

2.  Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver.

Authors:  Qi-Bo Wang; Bo-Kang Cui; Jian-Ming Weng; Qiu-Liang Wu; Ji-Liang Qiu; Xiao-Jun Lin
Journal:  J Gastrointest Surg       Date:  2012-07-06       Impact factor: 3.452

3.  The Clinicopathological and Imaging Characteristics of Primary Hepatic Carcinosarcoma and a Review of the Literature.

Authors:  Fengli Bin; Zhihong Chen; Peng Liu; Jianbin Liu; Zhiqun Mao
Journal:  J Hepatocell Carcinoma       Date:  2020-10-13

Review 4.  Surgical outcomes for 131 cases of carcinosarcoma of the hepatobiliary tract.

Authors:  Takehiro Okabayashi; Yasuo Shima; Jun Iwata; Tatsuo Iiyama; Tatsuaki Sumiyoshi; Akihito Kozuki; Teppei Tokumaru; Yasuhiro Hata; Yoshihiro Noda; Masanori Morita
Journal:  J Gastroenterol       Date:  2013-10-26       Impact factor: 7.527

Review 5.  Carcinosarcoma of the liver: report of a case.

Authors:  Takatsugu Yamamoto; Yukiko Kurashima; Kazunori Ohata; Ryoya Hashiba; Shogo Tanaka; Takahiro Uenishi; Koichi Ohno; Takashi Ikebe; Katsuhiko Miyaji; Nobusuke Fukumoto
Journal:  Surg Today       Date:  2013-05-05       Impact factor: 2.549

Review 6.  Primary carcinosarcoma of the liver: imaging features and clinical findings in six cases and a review of the literature.

Authors:  Jing Li; Pan Liang; Dandan Zhang; Jie Liu; Hongkai Zhang; Jinrong Qu; Jianbo Gao
Journal:  Cancer Imaging       Date:  2018-02-27       Impact factor: 3.909

7.  Primary hepatic carcinosarcoma with multimodal treatment.

Authors:  Daisuke Kurita; Yasuji Mokuno; Hideo Matsubara; Hirokazu Kaneko; Mikihiro Shamoto; Akira Satou; Shinsuke Iyomasa
Journal:  Nagoya J Med Sci       Date:  2018-08       Impact factor: 1.131

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.